All News

SH-110, a liquid cancer treatment for glioma, earned orphan drug status from the FDA, helping patients who struggle to swallow pills access therapy.

Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt.

A watercolor set gifted during my bone marrow transplant for acute myeloid leukemia became my outlet for wonder, creativity, and lasting joy in recovery and beyond.

Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.

Food insecurity is linked to a 28% higher risk of death among cancer survivors compared with those who have never received a cancer diagnosis, a new study found.

Dr. Olalekan O. Oluwole explained how CAR T is used to treat high-risk blood cancers and highlighted the potential of outpatient CAR T-cell therapy treatment.

Writing poems following my lymphoma diagnosis gave me hope and purpose as I endured chemo, helping me heal and share my experience with others.

Carotuximab plus Erleada proved safe in the first 10 patients with metastatic castration-resistant prostate cancer dosed on the phase 2 trial.

Outpatient CAR T therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.

Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.

Dr. Breelyn Wilky discusses challenges that patients with GIST face and shares advice with those who feel overwhelmed by the rarity of their condition.

Dr. Vincent Ma discussed the most recent and notable treatment updates for patients with high-risk and advanced melanoma.

Laura Yeager is a two-time breast cancer survivor. Catch up on all of Laura's blogs here!

Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated metastatic breast cancer.

Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.

I’m in remission from small lymphocytic lymphoma and off treatment, savoring this break while learning to live with the uncertainty that still lingers.

Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change care for patients in the future.

Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, according to Dr. Christina Poh.

A subtle ad about breast cancer self-checks led me to reflect on my own experience and the complex role of pharmaceutical companies in awareness.

In a candid interview with CURE, Terry Gillespie reflects on how her definition of survivorship has evolved from her lung cancer diagnosis to present day.

A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.

Dr. Breelyn Wilky urged newly diagnosed GIST patients to seek support from peers and advocacy groups, and to consult experts, even if care stays local.

During treatment for chronic lymphocytic leukemia and autoimmune anemia, I found relief and encouragement in a caring conversation with my oncology nurse.

The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.

Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will benefit from intensified treatment.

I was diagnosed with breast cancer, then lung cancer 17 years later — and both ultimately led me to make meaningful, positive changes in my life.

A patient on the Monjuvi trial saw lymph nodes shrink 85%, with stable results a year later, supporting the FDA’s recent approval for follicular lymphoma.

Thirteen years after cervical cancer, I’ve found strength in healing, grief in silence, and hope in sharing the quiet truths of survivorship.